Professional
Added to YB: 2024-02-26
Pitch date: 2024-01-15
NVO [bullish]
Novo Nordisk A/S
-54.19%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 701.05
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Polen Global Growth Added to Existing Position - Novo Nordisk
Novo Nordisk, new strategy addition, saw Q4 position building to avg weight. Danish pharma pioneer in insulin for diabetes, now focusing on GLP-1 drugs effective for blood sugar control & significant weight loss. With obesity a global epidemic causing adverse health outcomes, payors seen increasingly recognizing value of obesity treatments for patients & healthcare system over time.
Read full article (1 min)